A Harm ReductionApproach to Addressing the HIV,STIs,and Substance UseSyndemicAmong People Engaging in SexWork in Alabama
Project Number3P30AI027767-36S4
Former Number2P30AI027767-36
Contact PI/Project LeaderHEFFRON, RENEE A.
Awardee OrganizationUNIVERSITY OF ALABAMA AT BIRMINGHAM
Description
Abstract Text
PROJECT SUMMARY
Despite the availability of biomedical prevention tools to end the HIV epidemic, incidence of HIV and other STIs
in Alabama remain high, while uptake of prevention such as PrEP remains low. Sexworkers and people who
use drugs represent vulnerable groups who face unique barriers to HIV prevention including PrEP. However,
HIV services for sexworkers in Alabamaare limited, and no evidence-based interventions in the CDC’s
Compendium have been tailored for sexworkers. To assess syndemics trends among sexworkers in
Birmingham, in Year 1 of this study we analyzed 16 years of data from nearly 25,000 visits and over 17,000
individuals accessing services at Birmingham AIDS Outreach (community partner) and 1,185 individuals
reporting sexwork, finding elevated HIV and syphilis prevalence among sexworkers of color and elevated
HCV prevalence among non-Hispanic white sexworkers. In our qualitative interviews with 12 people engaged
in sexworkand five key informants from BAO and other organizations, we contextualized sexworkers’
experiences, finding that sexwork in Birmingham varies in terms of social and structural vulnerabilities and
HIV/STI risk. However, most programs offer tailored services to specific populations, and gaps in care remain.
Thus, using syndemic theory, we will develop an intervention for people engaging in sexwork in Alabama in
the proposed Year 2 of this study that builds on mixed methods data obtained in Year 1. The Specific Aims are
to: (1) Identify and characterize geographic clustering of sexworkand related outcomes among BAO clients,
(2) Develop a harm reduction intervention for people engaging in sexwork, and (3) Assess preliminary
acceptability, appropriateness, and feasibility of the intervention to increase PrEP uptake that responds to the
syndemics of sexwork, drug use, HIV,and STIs. In Aim 1, we will apply spatial epidemiologic methods to
identify geographic clustering of sexworkamong BAO clients; characterize cluster-level differences in clinical
and behavioral outcomes; and assess the relationship between neighborhood-level factors (e.g., structural
racism) and cluster- and individual-level clinical and behavioral outcomes. In Aim 2, the study team and Health
Equity Research Assembly (HERA) will develop the intervention using the principles of co-design, while in Year
3 we will evaluate the acceptability, appropriateness, and feasibility of the intervention using validated
measures through web-based surveys and qualitative interviews with sexworkers (n=5) and stakeholder
interviews with providers and other key informants (n=5). This work will be guided by the Consolidated
Framework for Implementation Research (CFIR), RE-AIM framework, and ERIC strategies. The project will
inform a subsequent R-level proposal to implement and evaluate the effectiveness of this novel intervention co-
developed with community members.
Public Health Relevance Statement
PROJECT NARRATIVE
The supplement project aims to develop a PrEP intervention for people engaging in sexwork in Alabama. The
project is grounded in syndemics theory and implementation science frameworks to directly address the needs
of an underserved population through community-academic partnership.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AIDS preventionAcquired Immunodeficiency SyndromeAddressAlabamaCOVID-19 pandemicCaringCharacteristicsClientClinicalClinical TrialsColorCommunitiesConsolidated Framework for Implementation ResearchDataDrug usageDrug userEpidemicEpidemiologic MethodsEvidence based interventionFaceFoodGender IdentityGeographyHIVHIV InfectionsHIV diagnosisHIV/STDHarm ReductionHealthHealth equity researchHealthcareHepatitis C PrevalenceHepatitis C virusHeterogeneityHousingIncidenceIndividualInjecting drug userInterventionInterviewMeasuresMethodsNeighborhoodsNot Hispanic or LatinoOnline SystemsOutcomePersonsPharmaceutical PreparationsPopulationPrevalencePreventionProviderReach, Effectiveness, Adoption, Implementation, and MaintenanceReportingResearchResourcesRiskRisk ReductionServicesStructural RacismSurveysSyphilisTarget PopulationsTestingUnderserved PopulationUnited StatesVisitVulnerable PopulationsWorkbehavioral outcomecommunity academic partnershipcommunity partnersdesigneffectiveness evaluationethnic identityevidence baseexperienceimplementation frameworkinformantmembermethod developmentnoveloutreachpre-exposure prophylaxispreventive interventionprogramsracial identityresponserole modelsexsocialsocial stigmaspatial epidemiologysubstance usesyndemicsystematic reviewtesting accesstheoriestherapy developmenttimelinetooltrenduptake
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
063690705
UEI
YND4PLMC9AN7
Project Start Date
01-March-1997
Project End Date
31-May-2029
Budget Start Date
05-September-2024
Budget End Date
31-May-2025
Project Funding Information for 2024
Total Funding
$216,498
Direct Costs
$150,000
Indirect Costs
$66,498
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$216,498
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 3P30AI027767-36S4
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 3P30AI027767-36S4
Patents
No Patents information available for 3P30AI027767-36S4
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 3P30AI027767-36S4
Clinical Studies
No Clinical Studies information available for 3P30AI027767-36S4
News and More
Related News Releases
No news release information available for 3P30AI027767-36S4
History
No Historical information available for 3P30AI027767-36S4
Similar Projects
No Similar Projects information available for 3P30AI027767-36S4